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Introduction.HepatitisCvirus(HCV)infectionisanindependentriskfactorforrenaltransplantation(RTx).Immunosuppression
minimization can render better quality of life to these patients. Methods. We analyzed 132 HCV-positive RTx patients (group A)
transplantedundertoleranceinductionprotocol(TIP)andcomparedthemwith79controls(groupB)transplantedusingstandard
tripledrugs.TIPconsistedof1donor-speciﬁctransfusion,peripheralbloodstemcellinfusion,portalinfusionofbonemarrow,and
target-speciﬁc irradiation. Their immunosuppression was cyclosporin, 2 ± 1mg/kgBW/day + prednisone, 10mg/day. Results.T I P
h a dn os i d ee ﬀects. Although unequal in size, the groups were well balanced. Group A patient survival at 1, 5, and 10 years was
92.4%, 70.4%, and 63.7%, respectively, versus 75.6%, 71.7%, and 55.7% in later, and graft survival was 92.9%, 81.5%, and 79.1%
versus 91.7%, 75.7%, and 67.7%, respectively. Mean serum creatinine (mg/dL) at these time periods in former was 1.38, 1.72, and
1.87, versus 1.3, 1.75, and 2.1 in later. Altered liver functions were noted in 22% patients in former versus 31% in later. Group A
had lesser rejection episodes. Conclusion. RTx using TIP in HCV-positive patients is a viable option with acceptable outcome.
1.Introduction
Hepatitis C virus (HCV) infection aﬀects 20–50% of end-
stage renal disease (ESRD) patients and contributes signiﬁ-
cantly to morbidity and mortality following renal transplan-
tation (RTx) [1, 2]. Approximately 8–28% of RTx patients
die due to chronic liver disease [3]. HCV infection has a
prevalenceofabout2.6–66%amongRTxpatientsindiﬀerent
countries with great genotype diversity in diﬀerent parts of
the world [3]. Antiviral drugs used for the management of
HCV can have graft-threatening eﬀects. In addition immu-
nosuppressants themselves can be life threatening to such
patients thereby putting the treating doctor in a serious
dilemma, and the patient in precarious position. In such sit-
uation transplantation after adequate antiviral therapy follo-
wed by minimal immunosuppression can be a good option.
This is a retrospective analysis of RTx carried out in
our center between 1998 to 2006 in HCV-positive patients
using specially designed tolerance induction protocol (TIP).
Standard RTx were compared to evaluate graft function and
graft/patient survival.
2.MaterialsandMethods
We analyzed medical records of HCV-positive patients
(tested by third-generation enzyme linked immunoassay
(ELISA)) who underwent RTx in our center from April
1998–2006 after adequate treatment. Patients were divided
into 2 groups; group 1 who were transplanted after TIP with
low-dose immunosuppression and group 2 who opted out
of TIP and were transplanted under standard triple drug im-
munosuppression.
Written consent forms for TIP were approved by institu-
tional review board. TIP consisted of the following steps
(Figure 1).
(1) HLA typing and lymphocyte cross-matching (LCM)
on day 1 followed by donor-speciﬁc transfusion2 Journal of Transplantation
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Figure 1: Tolerance induction paradigm for HCV-positive patients.
(DST; buﬀy coat infusion) in to RTx patient after
bleeding 330mL of blood from donor.
(2) Mobilization of donor stem cells by leucophoresis of
donor on day 3 after stimulating with granulocyte
colony stimulating factor (G-CSF), 7.5 microgram/
kgBW/day subcutaneously for 2 days (days 1, 2) and
infusing the collected peripheral blood stem cells
(PBSC) in to recipient’s periphery.
(3) Target-speciﬁc irradiation to subdiaphragmatic lym-
ph nodes, spleen, part of pelvic bones, and lumbar
vertebrae(200CGY ×4da ys)onda ys5to8.U nmod-
iﬁed cytokine stimulated donor bone marrow (BM;
200mL)infusionintraportallyonday10.Portalinfu-
siontechniqueofBMwascarriedoutbyomentalvein
cannulation under general anesthesia.
(4) LCM on day 12.
(5) RTx on day 15 with favorable LCM.
(6) Peritransplant immunosuppression induction of in-
travenous methylprednisone, 500mg on day before
transplant, on day of transplant, 500mg on 1st post-
operative day (POD), and then switched over to
oral prednisone, 30mg/day, tapered to 10mg/day by
the end of 3 months to be continued thereafter.
Cyclosporin (CsA), 3mg/kgBW/day from day before
transplant to be continued thereafter by monitoring
trough levels.
No immunological preconditioning of the recipient was
done. Graft-versus-host disease (GvHD) was ruled out by
monitoring absence of skin rashes, gastrointestinal symp-
toms,abnormalliverfunctiontests,andevidenceofBMsup-
pression.
2.1. HLA Typing and LCM. HLA typing and LCM were done
by conventional serological technique (one lambda predot
trayswereusedforHLAA,B,andDRtyping).LCMwasdone
by serological method using auto dithiothreitol and standard
cytotoxicity methods with T and B lymphocytes each.
2.2. Patient Demographics. Of 211 patients studied, group
A comprised of 132 patients who were transplanted under
TIP with low-dose immunosuppression. Group B consisted
of 79 patients, considered as controls who opted out of
protocol. Demographics of both groups were fairly balanced
(Table 1). Mean patient age of group A was 35.1 years with
Table 1: Demographics of renal transplant HCV-positive patients
(group A) and control patients (group B).
Patients (n = 211) Group A
(n = 132)
Group B
(n = 79)
Mean age (years; ± SD) 35.1 ±11.23 4 .2 ±11.4
Mean donor age (years; ± SD) 43.2 ±11.14 0 .6 ±11.4
Patient gender (male:female) 122:10 59:20
Third-party infusions 13 ±31 2 ±3
HLA match: n/6—in percentage
0 12.1 (n = 16) 5.1 (n = 4)
1 18.9 (n = 25) 7.6 (n = 6)
2 25.8 (n = 34) 10.1 (n = 8)
3 30.3 (n = 40) 34.1 (n = 27)
4 5.3 (n = 7) 8.9 (n = 7)
5 1.5 (n = 2) 3.8 (n = 3)
6 00
Not performed 6.1 (n = 8) 30.4 (n = 24)
Basic disease—in percentage
CGN 50 (n = 66) 45.6 (n = 36)
DM-DN 10.6 (n = 14) 3.8 (n = 3)
CTIN 14.4 (n = 19) 10.1 (n = 8)
Obstructive uropathy 4.6 (n = 6) 6.4 (n = 5)
ADPKD 1.5 (n = 2) 3.8 (n = 3)
Nephrosclerosis 12.1 (n = 16) 16.5 (n = 13)
FSGS 02 . 5 ( n = 2)
Membranous nephropathy 0.8 (n = 1) 2.5 (n = 2)
IgA nephropathy 01 . 2 6 ( n = 1)
MPGN 01 . 2 6 ( n = 1)
Vasculitis 0.8 (n = 1) 0
HUS 01 . 2 6 ( n = 1)
Lupus nephritis 2.2 (n = 3) 2.5 (n = 2)
Alport syndrome 1.5 (n = 2) 1.26 (n = 1)
Others 1.5 (n = 2) 1.26 (n = 1)
Abbreviations: ADPKD: autosomal dominant polycystic kidney disease;
CGN: chronic glomerulonephritis; CTIN: chronic tubulointerstitial nephri-
tis; DM-DN: diabetes mellitus, diabetic nephropathy; FSGS: focal segmental
glomerulosclerosis; HUS: hemolytic uremic syndrome; MMF: mycofenolate
mofetil; MN: membranous nephropathy.
92.4% males and in group B was 34.2 years, with 74.6%
males. Mean donor age was 43.2 years in the former and 40.6Journal of Transplantation 3
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Figure 2: (a) Kaplan curve for patient survival functions. (b) Kaplan curve for graft survival functions.
years in later. Donors were mainly parents, spouses/siblings
in both groups with mean HLA match 3 ± 1.2i nf o r m e r
and 3 ± 1.1 in later. The commonest etiology of CRF was
chronic glomerulonephritis (CGN) in both groups, with
50% patients in former and 34.2% having CGN in the later.
Mean third party infusions were 13 ±3i nf o r m e ra n d1 2±3
in the later.
2.3. Recipient Immunosuppression
Group A. CsA was the principal immunosuppressant with
prednisolone, 10mg/day. CsA doses were adjusted with an
intention to maintain trough blood levels of 50–176ngs/mL
(EMIT 2000 CsA assay, USA). Mean trough levels of CsA
were 180 ± 20ng/mL in 1st 2 months of transplantation and
tapered to maintain 100 ±15ng/mL thereafter.
Group B. In addition to the above drugs, group B received
mycophenolate mofetil (enteric coated), 360mg twice a
day/Azathioprine, 1.5mg/kgBW/day and doses adjusted ac-
cording to BM function.
2.4.RejectionandItsTreatmentinBothGroups. Protocolbio-
psies were performed at 100 days of stable graft function
in subset of patients. Rejection was diagnosed on biopsy,
reported as per modiﬁed Banﬀ criteria, and treated accord-
ingly [4, 5]. Rejections were treated with intravenous met-
hylprednisolone, 250mg/day × 3. Resistant rejections were
treated by CsA replacement with tacrolimus in both groups.
MMF/azoran was added in group A.
They were also covered with prophylaxis for CMV and
pneumocystis carinii. Eﬃcacy of protocol was tested by com-
paring patient and graft survival, incidence of rejections,
HCV reactivation, quality of graft function, and immuno-
suppression requirement.
2.5. Statistical Analysis. Students’ paired t-test was carried
out to compare the graft function in terms of SCr, rejection
episodes, and survival analysis. Survivals were examined
using Kaplan-Meier analysis and compared using the log-
rank test.
3. Results
Side eﬀects of G-CSF in donors were malaise, mild pyrexia,
and occasional skin rashes which responded to antipyretic
agents. The total average dose of CD34+ cells infused in
group A patients was 1.3 ± 1.43 × 106 cells/kgBW. Out of
132, 18 (13.6%) patients became positive on 12th day of TIP,
out of them, 11 patients became negative after waiting for
8–10 days and 7 patients underwent 2 plasmapheresis and
were put on MMF. They were transplanted after they became
negative (after 10–15 days).
Regarding transplantation surgery, mean donor data in
both groups was similar with mean warm-ischemia time of
25 ± 10 seconds, mean anastomosis time of 30 ± 10 minutes
and mean total operation time of 155 ± 20 minutes. Mean
followup of group A and B was 8.38 years and 8.95 years,
respectively. Mean patient survival in the former at 1, 3,
5, 7, and 10 years was 92.4%, 74.2%, 70.4%, 67.6%, and
63.7%, respectively, as compared to group B with 75.6%,
71.7%, 71.7%, 63%, and 55.7% survival, respectively. Mean
graft survival in the former at 1, 3, 5, 7, and 10 years was4 Journal of Transplantation
Table 2: Results.
Patients (n = 211) Group A (n = 132) Group B (n = 79) P value
Study period Jan 99–Dec 06 Jan 98–Dec 06
Mean followup (years; range) 8.38 ±2.2 (3.8–11.8) 8.95 ±2.2 (4–12.6)
Mean SCr (mg/dL) at
1 year 1.38 ±0.29 1.3 ±0.37 NS
3 years 1.55 ±0.34 1.58 ±0.64 NS
5 years 1.72 ±0.47 1.75 ±0.61 NS
7 years 1.8 ±0.39 1.97 ±0.73 NS
10 years 1.87 ±0.69 2.1 ±0.81 NS
Predominant biopsy
ﬁndings—percentage
Acute rejection episodes—percentage
Bcell mediated 8.3 (n = 11) 15.2 (n = 12) NS
Tcell mediated 8.3 (n = 11) 17.7 (n = 14) 0.03
Suspicious T/B 9.8/0 (n = 13/0) 20.2/5 (n = 16/4) 0.024/0.022
Acute CNI toxicity 12.1 (n = 16) 19 (n = 15) NS
Recurrence 1.5 (n = 2) 2.5 (n = 2) NS
Chronic rejections
Bcell mediated 3 (n = 4) 6.3 (n = 5) NS
Tcell mediated 3.8 (n = 5) 11.4 (n = 9) 0.029
IFTA 8.3 (n = 11) 19 (n = 15) 0.018
Chronic CNI toxicity 9.1 (n = 12) 16.5 (n = 13) NS
Recurrence 2.3 (n = 3) (ATIN) 3.8 (n = 2 (ATIN), n = 1( M P G N ) ) N S
De novo nephropathy 1 (MN) 0 NS
Chronic liver failure dueto reactivation 22 (n = 29) 31 (n = 25) P = 0.0002
Abbreviations:CNI:calcineurininhibitor;CGN:chronicglomerulonephritis;CsA:cyclosporinA;ELISA:enzymelinkedimmunoassay;ESRD:end-stagerenal
disease; G-CSF: granulocyte colony stimulating factor; HCV: hepatitis C virus; IFTA: unexplained interstitial ﬁbrosis and tubular atrophy; LCM: lymphocyte
cross-matching; PBSC: peripheral blood stem cells; POD: postoperative day; RTx: renal transplantation; SCr: serum creatinine; TIP: tolerance induction
protocol.
92.9%, 85.6%, 81.5%, 81.5%, 79.1%, respectively, as com-
pared to group B with 91.7%, 81.2%, 75.7%, 67.7%, 67.7%,
respectively. Kaplan Meier graphs of patient and graft sur-
vival are shown in Figures 2(a) and 2(b).
Graft function in terms of SCr (in mg/dL) in both groups
at 1, 3, 5, 7, and 10 years was 1.38 ± 0.29, 1.55 ±0.34, 1.72 ±
0.47, 1.8±0.39, and 1.87±0.69, versus 1.3±0.37, 1.58±0.64,
1.75±0.61, 1.97±0.73, and 2.1±0.81 in group B. Liver func-
tion status was deranged and accompanied by presence of
HCV-RNA (tested by PCR and 1 to 5 million copies/mL with
mean rate of 1.65 ± 0.75copies/mL in TIP and 2.3 ±
2.05copies/mL in controls were noted) in 22% (n = 29) pa-
tients of group A out of which 8.3% (n = 11) succumbed
to chronic liver failure and in 31% (25 patients) of group B,
16.5% (13 patients) died of chronic liver failure. Group A
patients had better graft and patient survival along with graft
function status as compared to group B (statistically not sig-
niﬁcant).
In terms of rejection there was statistically signiﬁcant
decrease in T-cell-mediated rejections and chronic changes
in the former as compared to the later (Table 2). Majority
of the patients responded to antirejection therapy. However
4/132 (about 3%) in TIP group and 4/79 (about 5%) in
controlgroupdidnotrespondandeventuallylosttheirgrafts
to chronic dysfunction and eventually succumbed to secon-
dary infections and septicemia. Incidence of reactivation of
HCV was also signiﬁcantly less in the former as compared
to controls. In TIP group totally 45 (34%) patients and in
controls 32 (40.5%) were lost over a followup of 12 years.
Out of these 11 in TIP and 13 in controls succumbed to liver
failure,otherstochronicgraftdysfunction-relatedmorbidity
or to septicemia. The other advantage in group A was signiﬁ-
cantly less requirement of maintenance immunosuppression
in the form of CsA, 2 ± 1mg/kgBW and prednisone, 5–
10mg/day versus group B with standard triple drug im-
munosuppression.
4. Discussion
The eﬀect of pretransplant HCV infection on survival of pa-
tients and grafts in RTx is controversial [6]. However, sur-
vival is better in HCV RTx patients as compared to dialysis
[7].The goals of pretransplantation HCV therapy are to
decrease the risk for progression of HCV-associated liver
disease, stabilize renal function in patients with HCV-rela-
ted glomerulopathy, and prevent development of HCV-as-
sociated disease after transplantation [8]. The use of immu-
nosuppression predisposes RTx patients to risks of derangedJournal of Transplantation 5
liver functions and mortality [9, 10]. A meta-analysis of
natural history of HCV in 6365 RTx patients showed that
anti-HCV antibody was an independent risk factor for death
and graft failure with relative risk of 1.79 [11]. In our center
we oﬀer TIP to all patients, and we start the protocol only
after informed consent form is signed by patient, donor,
and witness. However, all donors are not willing to undergo
stimulation protocols, abdominal fat resection, BM aspira-
tion, and above all they are not willing to wait till renal
transplantation.Weexplaintothemthatitmaytakeamonth
or little longer for transplantation, to ﬁnish the protocol and
if patient becomes lymphocyte cross-match positive, waiting
period can become longer. Many patients and donors cannot
get leave from their work for such a long period even if they
do not have to stay in hospital, they need to visit us fre-
quentlywhichtheyarenotwilling.Withminimizationofim-
munosuppression, patients are at lower risk of infections and
hence return to better quality of life. Secondly lowering of
rejection incidence and severity automatically saves ﬁnancial
burden, especially in India where there is no ﬁnancial sup-
port from government medicare/medical insurance. With
TIP, use of less number and low-dose of drugs brings down
the cost, though we have not touched upon this aspect here.
We have more than 10 years of experience of using TIP in
about 1500 patients and hence we modiﬁed it for HCV-
positive patients and implemented it [12]. Our study shows
that with use of tolerance induction protocol for HCV-posi-
tive patients, quality of life, graft function, and survival are
reasonablygoodevenforalongperiodoftenyears.Ourcon-
trol (group B) patients have reasonable quality of graft func-
tion and survival as found in other studies [6–11]. Interest-
ingly, tolerance induction protocol yielded signiﬁcantly less
chancesofreactivationofHCVascomparedtocontrols.This
could be attributed to better immune competence in these
patients since they require less immunosuppression.
5. Conclusion
RTx is an acceptable option for HCV-positive patients with
ESRD, and tolerance induction protocol is preferable over
standard triple drug immunosuppression in these group of
patients.
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